Literature DB >> 16297983

Changes in plasma amino acids after electroconvulsive therapy of depressed patients.

Johanna Palmio1, Martti Huuhka, Pirjo Saransaari, Simo S Oja, Jukka Peltola, Esa Leinonen, Jaana Suhonen, Tapani Keränen.   

Abstract

There are indications that mood disorders may be related to perturbations in the amino acid transmitters. The amino acids may thus be targets of treatment of depression. The purpose of this pilot study was to measure the acute effects of a single administration of electroconvulsive therapy (ECT) on the plasma levels of amino acids in depressed patients. ECT was administered to 10 patients with major depressive disorder. Altogether 23 plasma amino acids were analyzed before and at 2, 6, 24 and 48 h after ECT. The levels of glutamate and aspartate increased at 6 h after ECT compared with the baseline. Also the levels of total tryptophan increased 2-24 h after ECT. There were also elevations in other amino acids at 6 and 24 h. The levels of gamma-aminobutyric acid (GABA) decreased at 2 h. In this study the acute effects of single ECT were associated with changes in the levels of glutamate, aspartate, GABA, tryptophan and some other amino acids. The preliminary data suggest that the therapeutic effects of ECT in depression may be due to mechanisms involving these amino acid transmitters.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297983     DOI: 10.1016/j.psychres.2005.07.010

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Meta-analysis of central and peripheral γ-aminobutyric acid levels in patients with unipolar and bipolar depression.

Authors:  Bruno Romeo; Walid Choucha; Philippe Fossati; Jean-Yves Rotge
Journal:  J Psychiatry Neurosci       Date:  2017-10-02       Impact factor: 6.186

2.  Electroconvulsive therapy resolves cortical inhibition and manneristic omissions in a chronic catatonic patient.

Authors:  T Dresler; A S Giani; C Reinsberger; P Scheuerpflug; G Stöber; A J Fallgatter
Journal:  J Neural Transm (Vienna)       Date:  2010-09-01       Impact factor: 3.575

3.  Auditory processing of sine tones before, during and after ECT in depressed patients by fMRI.

Authors:  Martin Christ; Nikolaus Michael; Hermina Hihn; Anne Schüttke; Carsten Konrad; Bernhard T Baune; Andreas Jansen; Bettina Pfleiderer
Journal:  J Neural Transm (Vienna)       Date:  2008-03-04       Impact factor: 3.575

Review 4.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

5.  Decreased plasma neuroactive amino acids and increased nitric oxide levels in melancholic major depressive disorder.

Authors:  Yun-Rong Lu; Xin-Yan Fu; Li-Gen Shi; Yan Jiang; Juan-Li Wu; Xiao-Juan Weng; Zhao-Pin Wang; Xue-Yan Wu; Zheng Lin; Wei-Bo Liu; Hui-Chun Li; Jian-Hong Luo; Ai-Min Bao
Journal:  BMC Psychiatry       Date:  2014-04-27       Impact factor: 3.630

6.  Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.

Authors:  Lilly Schwieler; Martin Samuelsson; Mark A Frye; Maria Bhat; Ina Schuppe-Koistinen; Oscar Jungholm; Anette G Johansson; Mikael Landén; Carl M Sellgren; Sophie Erhardt
Journal:  J Neuroinflammation       Date:  2016-02-29       Impact factor: 8.322

Review 7.  Non-Invasive Brain Stimulation Effects on Biomarkers of Tryptophan Metabolism: A Scoping Review and Meta-Analysis.

Authors:  Cristian G Giron; Tim T Z Lin; Rebecca L D Kan; Bella B B Zhang; Suk Yu Yau; Georg S Kranz
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

8.  Study protocol for a randomized controlled trial to explore the effects of personalized lifestyle advices and tandem skydives on pleasure in anhedonic young adults.

Authors:  Eeske van Roekel; Maurits Masselink; Charlotte Vrijen; Vera E Heininga; Tom Bak; Esther Nederhof; Albertine J Oldehinkel
Journal:  BMC Psychiatry       Date:  2016-06-04       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.